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Large Varicose Vein Closure: A Comprehensive Review
Rawaa M. Almukhtar, MD, MPH,* and Mitchel P. Goldman, MD†

BACKGROUND Treatment of chronic venous disease and varicose veins has significant psychosocial and economic
impact. The great saphenous vein is a common vein to develop incompetence and reflux and, therefore, been the focus of
therapy for many years.
OBJECTIVE To review the published medical literature relating to large varicose vein closure and provide a guide for
closure techniques’ efficacy and safety.
METHODS A comprehensive search of the English language literature was performed up to and including December
2021. All references pertaining to large varicose vein closure were reviewed.
RESULTS There are multiple safe and effective minimally invasive methods to achieve occlusion of incompetent great
saphenous vein, the most widely used of which is endovenous thermal ablation. Other nonthermal, tumescent, and
nontumescent methods can also be used.
CONCLUSION Proper knowledge of vein anatomy, ultrasound, and vein closure procedures is needed to ensure safe and
effective outcomes.

C

hronic venous disease (CVI) and varicose veins are
commonly treated entities that have significant psychosocial and economic impact.1 The great saphenous vein (GSV) commonly develops valvular incompetence
and reflux leading to distal venous hypertension with its
adverse sequalae of superficial thrombophlebitis, deep vein
thrombosis (DVT), and cutaneous ulceration and, therefore,
has been the focus of therapy for many years.2 Whereas
surgical vein ligation and stripping was previously the only
reliable method to address GSV incompetence, this surgical
procedure gradually has been replaced due to the development of a variety of minimally invasive procedures
which have equivalent or better long-term outcomes with less
short-term complications and cost.1,2 Foremost among these
procedures are tumescent anesthesia–assisted endovenous
thermal ablation with laser or radiofrequency (EVTA). The
endovenous laser therapy (EVLT) procedure developed by
dermatologic surgeons, Robert Weiss and Mitchel Goldman,
brought together their knowledge of tumescent liposuction,
laser surgery, and ambulatory phlebectomy revolutionized
vascular surgery of the venous system. Additional treatments
include catheter-directed or ultrasound-guided foam sclerotherapy and endovenous cyanoacrylate adhesive vein closure which do not require tumescent anesthesia.3 More
recently, there are reports of tumescent-assisted catheterdirected foam sclerotherapy (CDFS).
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Nontumescent Nonthermal Methods
Polidocanol 1% Foam
Polidocanol 1% endovenous microfoam (PEM) (Varithena)
is FDA-approved for the treatment of incompetent GSV,
accessory saphenous veins, and visible varicosities of the
GSV system. This formulation is based on a patented
technology that produces cohesive, low-nitrogen microfoam coupled with a microfoam-generating device.4 The
cohesive microfoam fills the vein lumen leading to
circumferential contact and displacement of blood resulting
in efficient vein sclerosis.5,6 Before the approval of PEM, a
detergent solution such as sodium tetradecyl sulfate or
polidocanol was used as a sclerosant either as a liquid or
foamed to a thick consistency by rapidly agitating it with
room air in a ratio of solution to gas of 1: 4.7,8 In addition,
iodine solutions have also been used in liquid form as a
sclerotherapy agent for these large veins.8
Polidocanol 1% endovenous microfoam was studied in 2
Phase 3 randomized clinical trials, VANISH I and VANISH
II.9,10 In VANISH I, 279 patients were randomized to study
groups receiving 0.5%, 1%, or 2% PEM or control groups
receiving 0.125% PEM or placebo.10 Patients received 1 to 2
treatments of up to 15 mL of PEM per treatment session. The
GSV was cannulated at midthigh, and ultrasound-guided
injection of PEM was performed proximally 5 cm distal to the
saphenofemoral junction (SFJ). In total, 30 to 40 mm Hg
graduated compression stockings were used for 12 days, and
walking was encouraged for 5 minutes every waking hour for
1 week. Duplex response rate was recorded to be 59% in the
0.5% PEM group, 80% in the 1% PEM group, and 82% in
the 2% PEM group. A total of 5.5% of subjects in the
treatment group were reported to have venous thrombosis in
nontarget vein, most commonly at the common femoral vein
and popliteal vein. A total of 3.3% of patients in the treatment
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group were found to have a DVT. Patients were treated with
anticoagulation for a period of up to 3 months. No longerterm adverse events of PE reported. In VANISH II, 230
patients were treated with 0.125%, 0.5%, 1% polidocanol
foam, or placebo.9 Patients in the treatment group had 73%
response rate as assessed by duplex ultrasound. Common
adverse events after PEM treatment include retained coagulum, pain and discomfort in the extremity and injection site
hematoma, superficial thrombophlebitis, and extravasation.9
Pooled data from 1,333 PEM-treated patients in 12 clinical
trials showed a 7.2% rate of venous thrombosis, 2.9% of
which were diagnosed with common femoral vein thrombus
extensions and 2.9% were diagnosed with DVT.11

Cyanoacrylate Adhesive
A proprietary cyanoacrylate adhesive (VenaSeal, Medtronic
Plc, Dublin, Ireland) has been developed for permanent
closure of incompetent superficial truncal leg veins and was
FDA-approved in 2015.12 The adhesive is delivered through
a hydrophobic catheter advanced to a point 5 cm below the
SFJ. Cyanoacrylate adhesive (CA) triggers an acute inflammatory reaction in the vessel wall using a polymerization
reaction leading to encapsulation and vein fibrosis.12
In the first human use of endovenous CA for closure of
insufficient GSVs, 38 subjects at a single center with
symptomatic GSV reflux treated with CA had a 92% 12month target vein closure rate.13 A clinical trial across 10
centers in the United States14 randomized 222 patients to CA
or radiofrequency ablation (RFA). The anatomic success rate
was 100%, 97%, and 97% for CA and 87%, 94%, and 97%
for RFA, at 48-hour, 3-month, and 1-year follow-up. The
anatomic results for the CA group were proven noninferior to
the RFA group. No serious adverse events occurred in either
group, and no postprocedural DVT or thrombus extensions
into the common femoral vein were identified. Adverse events
were limited to phlebitis, paresthesia, pain during the procedure, access site infection, and ecchymosis. Postprocedure
compression stockings were used in both groups for 3 days
continuously and an additional 4 days during waking hours.
Another retrospective review of patients who underwent
CA treatment or RFA during a 3-year period showed a
treatment success of 99% and 100% in the groups,
respectively.15 One patient in each group had asymptomatic
proximal thrombus extension treated with anticoagulation
for 2 to 3 weeks. Three superficial infections from glue
clumps were noted in the CA group requiring excision and
drainage. Chronic foreign body reaction has also been
reported in CA-treated patients.16 One concern is the
possibility of recanalization of the treated vein with CA,
especially in veins larger than 6.6 mm.17

Tumescent Nonthermal Methods
Catheter-Directed Foam Sclerotherapy
With Tumescence of the Great
Saphenous Vein
Catheter-directed foam sclerotherapy is a modification of
usual ultrasound-guided foam sclerotherapy (UGFS) and
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was developed to increase the safety and effectiveness of the
method. It involves the positioning of a catheter ahead of the
saphenous trunk extension with the application of perivenous tumescent local anesthesia to reduce vein caliber and
intrasaphenous saline irrigation (ISI) to flush the blood out
of the vein before the SF delivery.18
A clinical trial by Santos and colleagues19 investigated 50
subjects which were randomized to 2 groups, ultrasoundguided foam sclerotherapy or CDFS with PST and ISI.
Although the success rate was higher in the CDFS group at
80% compared with 36% in UGFS at the 28-day follow-up,
6- to 12-month follow-up showed no significant difference
between the 2 groups. At 28 days, 12% in the CDFS with
PST and ISI group and 56% in the UGFS group required
retreatment.

Tumescent Thermal Method/
Endovenous Thermal Ablation
Endovenous thermal ablation is considered a first-line
modality for venous ablation.20 The thermal energy results
in vein wall thermal damage resulting in intimal destruction,
collagen denaturation of the media, and subsequent thrombotic and fibrotic vascular occlusion.21 There are 2 common
methods of delivering thermal energy: EVLT and RFA. The
procedure is usually performed under duplex ultrasonography
but may also be performed with direct insertion of the laser or
RFA fiber through externalization (phlebectomy) of the GSV.
The distal portion of the desired vein is accessed using a small
nick in the skin where the guide wire and catheter are inserted
and sent to the most proximal location of treatment, usually 2
to 2.5 cm distal to the SFJ.22,23 Ultrasound guidance can be
used to determine proper placement of the catheter. Alternatively, when laser ablation is performed, the localization of the
distal fiber is confirmed by visualization of the laser beam
through the skin. Tumescent anesthesia is administered to
decrease discomfort, compress the vein to maximize contact of
the thermal device with the vein wall, and to protect the
perivascular tissue.24 The thermal device is turned on, and the
catheter is slowly pulled back either manually or with a servo
device toward the distal aspect of the vein causing irreversible
thermal damage. To speed up the procedure and minimize
recurrence from distal perforators, Goldman1 recommended
that only the most proximal 20 cm of the GSV be treated with
EVTA and the remaining varicose GSV be treated with
ambulatory phlebectomy. Proebstle and colleagues25 confirmed that up to 30% of tributary veins do not resolve with
EVLT of the GSV alone, thereby necessitating removal with
ambulatory phlebectomy. A compression wrap is placed on
the treated leg with gauze to absorb the tumescent fluid
through the access or incision site, and a graduated
compression stocking is fitted to the leg the following day
after evaluating the status of the treated GSV and the deep
venous system.26

Endovenous Laser Ablation
The laser wavelengths used in EVLT that primarily target
tissue water (eg, 1,320 nm Nd:YAG laser, 1,470, 1,500 nm)
www.dermatologicsurgery.org
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have proven to be superior to those that primarily target
hemoglobin (810, 940, 980, 1,064 nm).2 A retrospective
study comparing EVTA using 1,320-nm laser, 810-nm
laser, and RFA found that 1,320-nm laser had the highest
success rate (p , .001). At the 1-year follow-up, success
rates for ablation using radiofrequency, 810-nm laser, and
1,320-nm laser were 78.2%, 80.8%, and 93.7%,
respectively.27
In 2001, the first case series suggesting that EVLT might
be successful in the treatment of large varicosities was
published.28,29 Multiple case series and systematic reviews
followed to document a success rate of at least 90% of
EVLT in most of these studies.30–32 In a study by Goldman
and colleagues,26 24 patients with incompetent GSV
(0.5–1.2 cm in diameter) were treated with a 1,320-nm
intravascular laser with an automatic pull back mechanism
at 1 mm/s. Subjects were follow-up for 6 months to 1 year
post-treatment. All subjects demonstrated complete closure
of the incompetent GSV assessed by duplex ultrasound and
relief of preoperative symptoms. There were no noted
complications. Most adverse events reported are minor and
self-limited and include postprocedural pain, ecchymosis,
hematoma, superficial thrombophlebitis, hyperpigmentation, and paresthesia.30 These common adverse events
disappear spontaneously within 2 weeks and/or can be
controlled by graduated compression stockings and antiinflammatory agents.21 The likelihood of DVT is less than
1%.33,34 Skin burns are also rare and may occur if the
energy level is too high, if superficial veins are treated, and/
or the cooling effect of tumescent anesthesia is insufficient.
Caution is warranted for the extrafascial part of the truncal
varicose veins and the cutaneous exit site of the laser fiber.

which is termed endovenous heat-induced thrombosis (EHIT)
and refers to the extension of thrombus from the ablated
superficial vein into the deep vein.45 The meta-analysis
revealed that EHIT occurred in 1.4% of cases. Early
ambulation and thromboprophylaxis in high-risk patients
can reduce the risk of thrombotic events.20 We have never seen
a thrombotic adverse event because our patients are treated
entirely with tumescent anesthesia, are ambulatory immediately after the procedure, and we only treat 1 leg at a time to
ensure proper ambulation.46–48 Of note, Lawrence and
colleagues49 suggested that GSV diameter at the SFJ of more
than 8 mm and a history of DVT were associated with
increased risk of EHIT in RFA-treated subjects. Interestingly, a
study by Vasquez and colleagues50 showed factors associated
with improved occlusion rates included increasing age, female
sex, and volumes greater than 250 mL of tumescent
anesthesia. The authors theorized that increased failure rates
associated with male sex and younger age are secondary to
variations in collagen and inflammation in these populations.
Of note, several studies compared the efficacy of RFA
with EVLT and found that the latter has a slightly higher
closure rate (by 2%–14%) when compared with
RFA.41,51,52 Other studies found the 2 methods equally
effective. The combination of EVLT techniques with
ambulatory phlebectomy can be very effective in eliminating varicose tributaries.1 Indeed, the 2 procedures may even
provide a synergistic effect because single isolated phlebectomies have shown benefit in reducing GSV incompetence.21 The area surrounding the distal tributaries to be
treated is infiltrated with tumescent anesthesia. After
treating the GSV with EVTA, the varicose tributaries are
removed using a standard ambulatory phlebectomy
technique.1

Endovenous Radiofrequency Ablation
The initial system, developed in part by Mitchel Goldman
and Robert Weiss, treated 2- to 12-mm veins. The first longterm, large, single-center case series to investigate efficacy of
RFA by Weiss & Weiss showed that RFA was effective in
approximately 90% of 140 limbs after 2 years.35 This study
also showed that 98% of patients were satisfied with this
intervention. A multicenter study that included 1,222 limbs
showed anatomic success rates and patient satisfaction in
more than 85% of the people after 4 years of follow-up.36
Several studies that followed confirmed a closure rate with
RFA of 86% to 100%.37–41
Similar to EVLT, RFA is associated with minor and selflimiting complications including paresthesia, ecchymosis, and
skin pigmentation.38 Radiofrequency ablation was found to
be associated with lower rate of postoperative pain and
ecchymosis when compared with EVLT.42 Skin burns and
phlebitis are reported in approximately 2% to 5% of cases.43
A recent systemic review and meta-analysis of incidence of
thrombotic events after GSV thermal ablation found that DVT
occurred infrequently in 0.3% of cases and PE occurred in
0.1% of cases.44 Similar results of thrombotic events were
found when RFA and EVLT groups were analyzed separately.
The routine use of duplex surveillance has led to the
description of a new form of localized postoperative DVT
Varicose Vein Management • Almukhtar and Goldman

Conclusion
Treatment of CVI and varicose veins has a significant
psychosocial and economic impact. There are multiple safe
and effective minimally invasive methods to achieve
occlusion of incompetent GSV, the most widely used of
which is EVTA. In our clinical experience, the best results
can be seen with therapies using RFA and EVLA with
1,320-nm laser. Proper knowledge of vein anatomy,
ultrasound, and vein closure procedures are needed to
ensure safe and effective outcomes.
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